Tetrahydrocurcumin, a colorless form of curcumin sold as a dietary supplement, is marketed as a more stable, better-absorbed source of curcumin's proposed anti-inflammatory and cell-protective effects. Lifespan and organ-protection effects come only from animal studies. Human evidence is thin and mixed, much of it from the main manufacturer; Europe's daily limit is below trial doses, and rare turmeric-linked liver injury remains a concern: a plausible but largely untested longevity candidate. (Full Review)
| Marker | Target | Why |
|---|---|---|
| ALT | 7–56 U/L | Safety check: rise stops use |
| AST | 10–40 U/L | Safety check: rise stops use |
| Total bilirubin | 0.1–1.2 mg/dL | Safety check: rise stops use |
| INR (warfarin users only) | Prescriber's individual range | Safety check: rise changes use |
| Fasting glucose (users of glucose-lowering drugs) | 70–99 mg/dL | Safety check: low values change use |
| hs-CRP | Change from own baseline | Expected to change; proposed anti-inflammatory effect, unproven in humans |
Cadence: Baseline before starting; liver enzymes at 4–6 weeks and 3 months, then every 6–12 months; INR within 1–2 weeks of starting or stopping (warfarin users); more frequent home glucose checks in the first month (diabetes medication); immediate testing at jaundice, dark urine or abdominal pain